Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for interstitial lung disease. Iconovo AB (publ) was founded in 2013 and is headquartered in Lund, Sweden.
Metrics to compare | ICO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipICOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.6x | 35.4x | −0.5x | |
PEG Ratio | −0.05 | −0.54 | 0.00 | |
Price/Book | 1.0x | 5.5x | 2.6x | |
Price / LTM Sales | 7.7x | 5.7x | 3.1x | |
Upside (Analyst Target) | −10.3% | 42.1% | 58.4% | |
Fair Value Upside | Unlock | 12.5% | 9.3% | Unlock |